Intriguing Research into Pathways to Limit Nicotine, Quit Cigarette Use
NetworkNewsWire Editorial Coverage
09 Jan, 2018, 13:30 GMT
NEW YORK, January 9, 2018 /PRNewswire/ --
It's no secret that cigarettes, a product whose toxins and carcinogens have shown time and again to cause illness and a long list of cancers, are addictive. Finding a way to stop smoking is an individual battle, although there is hope that new products are on the horizon that may help millions of people win the fight. Several significant research and development projects being undertaken by such innovators such as Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) (LXRP Profile) a company with proprietary technology capable of changing the way active pharmaceutical ingredients ("APIs") such as nicotine enter the body. Even leading tobacco brands like British American Tobacco p.l.c. (NYSE: BTI), Philip Morris International (NYSE: PM), Altria Group Inc. (NYSE: MO) and Universal Corporation (NYSE: UVV) are showing interest in contributing to the shift toward nicotine-infused products and away from combustible cigarettes.
What, No Smoke?
That's the goal, isn't it? Products on the market today meant to help smokers "kick the habit" are behind the counter of nearly every store that carries dozens of cigarette brands. The U.S. Food and Drug Administration has approved several forms of nicotine replacement therapy such as gum, transdermal patches, sprays, inhalers or lozenges, and all are meant to help relieve some of the physical withdrawal symptoms when a person tries to quit smoking (http://nnw.fm/2Nd9L). Interestingly, the legal age for tobacco products and inhalant delivery system such as e-cigarettes in Oregon was just raised from 18 to 21, effective January 1, 2018. That legislation puts Oregon in company with California, Hawaii, Maine and New Jersey as the only states with such a legal limit (http://nnw.fm/d12X2). The goal, according to state officials, is to stop young people from first picking up a cigarette and avoid joining the millions of people who die each year because of tobacco use.
Promising Research
Research teams at Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), based in Kelowna, British Columbia, Canada, have developed a new, disruptive drug delivery platform called "DehydraTECH™ that changes the way APIs enter the body via oral consumption. Lexaria's patented delivery method could give the estimated 69 percent of U.S. adult smokers who say they want to quit a new way to do just that. Utilizing Lexaria's DehydraTECH™ technology to formulate edible products containing nicotine and/or its analogues for this purpose offers unique advantages to the consumer. The company's newly issued U.S. patent award covers the use of DehydraTECH™ technology as a broad delivery platform for a broad range of APIs, including all cannabinoids, fat soluble vitamins, non-steroidal anti-inflammatory pain medications ("NSAIDs"), and nicotine (http://nnw.fm/Do3iO).
"This wide-ranging patent allowance from the U.S. Patent and Trademark Office exceeds our expectations" Lexaria Bioscience Chief Executive Officer Chris Bunka stated in a press release (http://nnw.fm/4NAWd). "This vastly expanded intellectual property protection will enable us to aggressively pursue new business opportunities in 2018 such as what could be the world's first nicotine edibles for the smokeless tobacco industry, or enhanced products for NSAID-derived pain management, as well as in the rapidly growing cannabis market."
Advanced Delivery Method
Lexaria is accelerating its research focus on nicotine following its patent grant and is preparing formulations of edible forms of nicotine using the DehydraTECH™ technology. These formulations are currently completing quality control testing prior to in vivo absorption and tolerability testing. A third-party laboratory is expected to perform the first nicotine edible tests in February 2018. Imagine an edible nicotine-infused product that: masks unwanted tastes, eliminating the need for sugar-filled edibles; reduces the time of onset with effects felt within 15-20 minutes instead of up to an hour or more; avoids first-pass liver metabolism, which means fewer side effects; and increases bio-absorption by five to 10 times which equates to an inhaled delivery method - all while helping you quit smoking cigarettes.
Spotlight on Innovation
The FDA's recent proposal to reduce nicotine levels in cigarettes to non-addictive levels bodes well for companies like Lexaria whose patented technology clearly supports the effort. Almost 90 percent of adult smokers started smoking before the age of 18 and nearly 2,500 youth smoke their first cigarette every day in the U.S., and the FDA's comprehensive plan for tobacco and nicotine regulation will serve as a multiyear roadmap to better protect children and significantly reduce tobacco-related disease and death (http://nnw.fm/2SUkk). Lowering nicotine levels could decrease the likelihood that future generations become addicted to cigarettes and allow more currently addicted smokers to quit.
Market Implications
The company's proprietary platform allows for the infusion of nicotine molecules within a wide range of edible food ingredients or typical capsule formats, effectively opening the door for the creation of a new product category targeting the high-demand smoking cessation market (http://nnw.fm/vmNg7). While this research is in its early stages, the market implications of maximizing Lexaria's patented molecular delivery method in such areas as nicotine delivery, non-steroidal anti-inflammatories (NSAIDs) and vitamins - all multibillion dollar industries - is significant. According to a 2016 report by Grand View Research, Inc., the global smoking cessation and nicotine de-addiction market is expected to reach over $21.8 billion by 2024. As Grand View reports, "The launch of… improved and innovative nicotine replacement therapy products is to serve as a high impact rendering driver for the growth of the smoking cessation and nicotine de-addiction market (http://nnw.fm/Ytnr1)"
Big Tobacco's Take
The FDA's mandate is even being touted by big tobacco companies whose fortunes once solely rested on its combustible offerings. Smoke-free options are rapidly becoming popular as the National Institute on Drug Abuse reports they often are chosen by those wishing to lower nicotine cravings in their quest to stop smoking cigarettes (http://nnw.fm/bM5vN). The FDA's directive to lower nicotine in cigarettes to non-addictive or less addictive levels is driving much of the industry's research and development drive. With more tobacco companies acknowledging the hazards of smoking and changing their approach to nicotine consumption, Lexaria could have incredible potential as a solution provider with its advanced delivery system.
British American Tobacco p.l.c. (NYSE: BTI), a global tobacco and nicotine products company, sells its products in more than 200 markets worldwide. The company's push to develop "Next Generation Products," such as e-cigarettes and tobacco-heating products comes with a reminder that although these products are not entirely without risk, they are considered to be significantly less than smoking combustible cigarettes (http://nnw.fm/ss8Nv).
Philip Morris International (NYSE: PM), one of the three largest tobacco companies in the world, trumpets its intention to design a "smoke-free future" right on the front page of the company website, asking readers "How long will PMI be in the cigarette business?" (http://nnw.fm/7Mih6). The company states it is developing and testing products that deliver nicotine without the harmful smoke of cigarettes. In fact, Phillip Morris said its New Year's resolution is to give up cigarettes (http://nnw.fm/Q2Dc1) and took out full-page ads in several newspapers in the United Kingdom that reiterated its ambition.
Altria Group Inc. (NYSE: MO) is another global tobacco company based in the United States focused on addressing these same issues of reducing the health effects of tobacco use. "Reduced risk" tobacco products are reportedly part of Altria's future, with many industry analysts expecting this category to be a major growth driver in 2018 (http://nnw.fm/vr3Ys). Regulatory hurdles along with limitations on marketing campaigns, a growing anti-smoking push and higher excise taxes are all dragging tobacco companies down.
Leading tobacco leaf supply company Universal Corporation (NYSE: UVV) doesn't make cigarettes or tobacco products, but the Virginia-based company is still affected by the public's growing aversion to combustible cigarettes. Universal states on its website that the company believes growth in world consumption of cigarettes peaked several years ago and is declining. While its clients remain the six largest tobacco companies in the world, Universal is also investing in alternative forms of revenue (http://nnw.fm/0VKe0). The company's AmeriNic joint venture seeks to produce liquid nicotine for the vapor products industry, which may prove to be a lucrative change from the conventional tobacco end market.
A Bright Future
Lexaria, which upgraded to the OTCQB Venture Market on January 4, 2018, expects this to provide an unqualified positive opportunity for investors as the company continues to build its disruptive technology and create innovative products for the cannabis industry and nicotine-suppression markets.
"Lexaria has made notable progress over the past twelve months in all aspects of its business, and will receive even more recognition by upgrading to OTCQX," CEO Bunka stated in the press release announcing the uplisting. "Lexaria expects to provide greater visibility and liquidity for our investors on OTCQX as we build our disruptive technology innovations through 2018 and beyond."
For more information on Lexaria Bioscience, visit: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with NNW or any company mentioned herein. The commentary, views and opinions expressed in this release by NNW are solely those of NNW and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW and FNM for any investment decisions by their readers or subscribers. NNW and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment.
NNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW and FNM undertake no obligation to update such statements.
NetworkNewsWire (NNW) is affiliated with the Investor Based Brand Network (IBBN).
About IBBN
Over the past 10+ years we have consistently introduced new network brands, each specifically designed to fulfil the unique needs of our growing client base and services. Today, we continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Please feel free to visit the Investor Based Brand Network (IBBN) www.InvestorBasedBrandNetwork.com
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
+1-212-418-1217 Office
Media Contact:
FN Media Group, LLC
+1-(954)345-0611
SOURCE NetworkNewsWire